检索结果-南通市图书馆

XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer:An open-labeled,multicenter,randomized,prospective phase III trial(EXELOX)

引用

Cancer Communications 2022年第4期42卷 314-326页

作者： Xiao-Dong Zhu Ming-Zhu huang Yu-Sheng Wang Wan-Jing Feng Zhi-Yu chen Yi-Fu He Xiao-Wei zhang Xin Liu chen-chen Wang wen zhang Jie-Er Ying jun wu Lei Yang Yan-Ru Qin Jian-Feng Luo Xiao-Ying Zhao wen-hua Li Zhe zhang Li-Xin Qiu Qi-Rong Geng Jian-Ling Zou Jie-Yun zhang Hong Zheng xue-Feng Song shu-Sheng wu cheng-Yan zhang Zhe Gong Qin-Qin Liu Xiao-Feng Wang Qi xu Qi Wang Jian-Mei Ji Jian Zhao Wei-Jian Guo department of Gastrointestinal Medical Oncology Fudan University Shanghai Cancer CenterShanghai 200032P.R.China department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032P.R.China department of Gastroenterology Shanxi Cancer HospitalTaiyuanShanxi 030013P.R.China department of Medical Oncology The First Affiliated HospitalDivision of Life Science and MedicineUniversity of Science and Technology of ChinaHefeiAnhui 230031P.R.China department of Abdominal Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)Institute of Cancer and Basic Medicine(IBMC)Chinese Academy of SciencesHangzhouZhejiang 310005P.R.China department of Medical Oncology The First People’s Hospital of ChangzhouChangzhouJiangsu 213004P.R.China department of Gastroenterology Nantong Tumor HospitalNantongJiangsu 226006P.R.China department of Oncology Zhengzhou University First Affiliated HospitalZhengzhouHenan 450052P.R.China department of Biostatistics School of Public HealthFudan UniversityShanghai 200032P.R.China department of medical oncology Cancer Hospital of Fudan UniversityMinhang BranchShanghai 200032P.R.China

Background:There is no consensus on whether triplet regimen is better than doublet regimen in the first-line treatment of advanced gastric cancer(AGC).We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine(XELOX)and epirubicin,oxaliplatin,plus capecitabine(EOX)regimens in treating ***:This phase III trial enrolled previously untreated patients with AGC whowere randomly assigned to receive the XELOXor *** primary endpoint was non-inferiority in progression-free survival(PFS)for XELOX as compared with EOX on an intention-to-treat ***:Between April 10,2015 andAugust 20,2020,448AGCpatientswere randomized to receive XELOX(n=222)or EOX(n=226).The median PFS(mPFS)was 5.0 months(95%confidence interval[CI]=4.5-6.0 months)in the XELOX arm and 5.5 months(95%CI=5.0-6.0 months)in the EOX arm(hazard ratio[HR]=0.989,95%CI=0.812-1.203;P_(non-inferiority)=0.003).There was no significant difference inmedian overall survival(mOS)(12.0 vs.12.0months,P=0.384)or objective response rate(37.4%vs.45.1%,P=0.291)between the two *** patients with poorly differentiated adenocarcinoma and liver metastasis,the EOX arm had a significantly longer mOS(P=0.021)and a trend of longer mPFS(P=0.073)than the XELOX *** rate of grade 3/4 adverse events(AEs)was 42.2%(90/213)in the XELOX arm and 72.5%(156/215)in the EOX arm(P=0.001).The global health-related quality of life(QoL)score was significantly higher in the XELOX arm than in the EOX arm during ***:This non-inferiority trial demonstrated that the doublet regimen was as effective as the triplet regimen and had a better safety profile and QoL as a first-line treatment for AGC ***,the triplet regimen might have a survival advantage in patients with poorly differentiated adenocarcinoma and liver metastasis.

关键词： Advanced gastric cancer chemotherapy XELOX doublet regimen EOX triplet regimen noninferiority quality of life phase III trial

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Caspase-3激活和细胞色素c释放在脑缺血再灌注损伤中的作用

引用

山东大学学报（医学版） 2007年第12期45卷 1193-1196,1200页

作者：张文华周璐徐淑军陈腾贾德泽周茂德吴承远山东大学齐鲁医院神经外科济南250012

目的探讨Caspase-3激活和细胞色素c释放在脑缺血再灌注损伤后神经元细胞凋亡中的作用。方法利用MACo法建立小鼠急性脑缺血模型，以酶活性测定、Western杂交和免疫组化等方法对Caspase-3活性变化和激活以及细胞色素c释放进行规律性观察... 详细信息

目的探讨Caspase-3激活和细胞色素c释放在脑缺血再灌注损伤后神经元细胞凋亡中的作用。方法利用MACo法建立小鼠急性脑缺血模型，以酶活性测定、Western杂交和免疫组化等方法对Caspase-3活性变化和激活以及细胞色素c释放进行规律性观察。结果①脑缺血再灌注损伤后3hCaspase-3活性即开始升高，并随时间延长而进一步升高，12—24h达到高峰；②脑缺血再灌注损伤后6hCaspase-3明显激活，手术组是假手术组的7．6倍（P〈0．01）；③脑缺血再灌注损伤后6h细胞色素c明显释放，手术组是假手术组的8．5倍（P〈0．01）。结论脑缺血再灌注损伤后早期Caspase-3明显激活，细胞色素c明显释放，表明Caspase-3激活和细胞色素c释放参与了脑缺血再灌注损伤早期过程，有助于进一步研究脑缺血再灌注损伤的机制。

关键词：脑缺血再灌注损伤 Caspase-3 细胞色素c

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan xu-Yong Wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He wen-Zhi Guo Liu-Gen Lan xu-Yong Sun Dong chen Zhi-shui chen Da-Wei zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-hua Shi Bo Wang Jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong wu Chang-Jiang Lu Cai-de Lu Dong-hua zhang xuan Wang Zi-Qiang Li Mu-Jian teng jun-Jie Li wen-Tao Jiang Jian-hua Li Quan-Bao zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-zhou Wang Zheng Wang Jian zhou Gang chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-zhou Si Bin Xie Xiao-shun He Zhi-Yong Guo shu-Sen Zheng Xiao xu department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Data release of the LAMOST pilot survey

引用

Research in Astronomy and Astrophysics 2012年第9期12卷 1243-1246页

作者： A-Li Luo Hao-Tong zhang Yong-Heng Zhao Gang Zhao Xiang-Qun Cui Guo-Ping Li Yao-Quan Chu Jian-Rong Shi Gang Wang Jian-Nan zhang Zhong-Rui Bai Xiao-Yan chen Feng-Fei Wang Yan-Xin Guo Jian-jun chen Bing Du Xiao Kong Ya-Juan Lei Yin-Bi Li Yi-Han Song Yue wu Yan-Xia zhang Xin-Lin zhou Fang Zuo Peng Du Lin He wen Hou Yi-Qiao Dong Jian Li Guang-Wei Li shuang Li Jing Song yuan Tian Meng-Xin Wang Yong-Hui Hou Zhi-Ying Huo Hong-Zhuan Hu Ning-Sheng Hu Zhong-wen Hu Lei Jia Fang-hua Jiang Xiang Jiang Zi-Bo Jiang Ge Jin Ai-hua Li Qi Li Yin-Dun mao Zheng-Hong Tang Qing-Sheng Tao Liang-Ping Tu Da-Qing Wang Dan Wang Jian-Ping Wang Lei Wang Shou-Guan Wang shu-Qing Wang Ya-Nan Wang You Wang Yue-Fei Wang Ming-Zhi Wei Xiang-Xiang xue Xiao-Zheng Xing Ling-Zhe xu Xin-Qi xu Yan xu de-hua Yang Shi-Hai Yang Zheng-Qiu Yao Yong Yu Hui yuan Chao Zhai En-Peng zhang Jing zhang Li-Ping zhang Weizhang Yong zhang Zhen-Chao zhang Ming Zhao Fang zhou Yong-Tian Zhu Jie Zhu Si-cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China lal @ lamost o rg Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Technologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture design and Research Chinese Academy of Sciences Beijing 100190China

This paper describes the data release of the LAMOST pilot survey, which includes data reduction, calibration, spectral analysis, data products and data access. The accuracy of the released data and the information about the FITS headers of spectra are also introduced. The released data set includes 319 000 spectra and a catalog of these objects.

关键词： techniques: spectroscopic survey — data reduction — data release

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

引用

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie wu shu-wei Duan Hong-tao Yang Yue-yi deng Wei Li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan Lin Zhi-yong Guo jun Zhu Jing-ai Fang xu-sheng Liu Li-hua Wang Rong Wang Nian-song Wang Xiao-hong cheng Li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu chen wen-hu Liu Hong-li Lin Meng Liang Lu Ma Ming chen Li-qun Song Jian chen Qing Zhu Chang-ying Xing Yun Li Ji-ning Gao Rong-shan Li Ying Li Hao zhang Ying Lu Qiao-ling zhou jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei chen department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China department of Nephrology Tianjin Medical University General HospitalTianjin 300052China department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pdecreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China:focus on the safety

引用

Infectious Diseases of Poverty 2021年第2期10卷 75-76页

作者： Jing-Tao Gao Juan Du Gui-Hui wu Yi Pei Meng-Qiu Gao Leonardo Martinez Lin Fan Wei chen Li Xie Yu chen hua Wang Long Jin Guo-Bao Li Pei-Lan Zong Yu Xiong Qian-Hong wu Ming-wu Li Xiao-Feng Yan Yan-Fang Miao Qing-Shan Cai Xin-Jie Li Da-Peng Bai shu-jun Geng Guo-Li Yang Pei-junTang Yi Zeng Xiao-Hong chen Tong-Xia Li Cui Cai Yun zhou Ma Zhuo Jian-Yun Wang wen-Long Guan Lin xu Ji-Chan Shi Wei shu Li-Li cheng Feiteng Yu-Jia Ning Shi-Heng Xie Yu-Xian Sun Li-Jie zhang Yu-Hong Liu Clinical Center on TB Beijing Chest HospitalCapital Medical University/Beijing Tuberculosis and Thoracic Tum or Research InstituteNo 9Beiguan StreetTongzhou DistrictBeijing 101149Peopled Republic of China 不详

Background:World Health Organization recommends countries introducing new drug and short treatment regimen for drug resistant tuberculosis(DR-TB)should develop and implement a system for active pharmacovigilance that allows for detection,reporting and management of adverse *** aim of the study is to evaluate the frequency and severity of adverse events(AEs)of bedaquiline-containing regimen in a cohort of Chinese patients with multidrug-resistant(MDR)/extensively drug-resistant(XDR)-TB based on active drug safety monitoring(aDSM)system of New Drug Introduction and Protection Program(NDIP).

关键词： Tuberculosis Multidrug-resistant Bedaquiline Safety Surveillance program China

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

肺癌适应性治疗中国专家共识

引用

循证医学 2024年第4期24卷 193-200页

作者：吴一龙陆舜程颖周清张嘉涛潘燚汪斌超韩宝惠陈海泉周清华王绿化陈明王洁周彩存刘晓晴马智勇黄诚宋启斌莫树锦钟文昭朱正飞宋勇陈蓉蓉陈克终刘基巍杨帆胡晓桦胡毅杨懿岳东升王群赵军范江陈椿孟庆威闫小龙董晓荣朱波邢力刚李兆澄李子明褚倩陈元林根段建春田攀文范云刘安文刘慧刘哲峰杨农汪步海张同梅信涛刘思阳王志杰马锐于起涛林劼涂海燕姚煜赵明芳王慧娟张海波蔡尚立张绪超李慧杜瀛瀛吴芳严令华崔久嵬王燕邬麟周建娅汪笑男黄媚娟冯卫能周进李力中国抗癌协会肺癌专业委员会广东省临床试验协会/中国胸部肿瘤研究协作组广东省肺癌研究所南方医科大学附属广东省人民医院(广东省医学科学院)广州510080 上海交通大学医学院附属胸科医院上海200030 吉林省肿瘤医院长春130021 复旦大学附属肿瘤医院上海200032 四川大学华西医院成都610041 中国医学科学院肿瘤医院深圳医院广东深圳518116 中山大学肿瘤防治中心广州510060 中国医学科学院肿瘤医院北京100021 同济大学附属上海市肺科医院上海200433 解放军总医院第五医学中心北京100039 郑州大学附属肿瘤医院/河南省肿瘤医院郑州450003 福建省肿瘤医院福州350011 武汉大学人民医院肿瘤中心武汉430060 香港中文大学医学院中国香港东部战区总医院南京210002 北京吉因加科技有限公司北京102206 北京大学人民医院北京100044 大连医科大学附属第一医院辽宁大连116011 广西医科大学第一附属医院南宁530020 解放军总医院北京100071 成都市第三人民医院/西南交通大学医学院成都610031 天津医科大学肿瘤医院天津300060 复旦大学附属中山医院上海200032 北京大学肿瘤医院北京100142 上海交通大学附属上海市第一人民医院上海200025 福建医科大学附属协和医院福州350001 哈尔滨医科大学附属肿瘤医院哈尔滨150081 空军军医大学唐都医院西安710038 华中科技大学同济医学院附属协和医院武汉430022 陆军军医大学第二附属医院-新桥医院重庆400037 山东省肿瘤医院济南250117 华中科技大学同济医学院附属同济医院武汉430030 中国医学科学院肿瘤医院山西医院太原030013 中国科学院大学附属肿瘤医院/浙江省肿瘤医院杭州310022 南昌大学附属第二医院南昌330006 湖南省第二人民医院长沙410035 南京大学医学院附属苏北人民医院江苏扬州225001 首都医科大学附属北京胸科医院北京101149 哈尔滨医科大学附属第二医院哈尔滨150001 暨南大学附属第一医院广州510630 辽宁省肿瘤医院沈阳110042 广西医科大学附属肿瘤医院南宁530012 昆明医科大学第二附属医院昆明650101 西安交通大学第一附属医院西安710061 中国医科大学附属第一医院沈阳110001 广东省中医院广州510120 广州燃石医学检验所有限公司广州510300 安徽医科大学第一附属医院合肥230022 中南大学湘雅二医院长沙410011 上海桐树生物科技有限公司上海200444 吉林大学白求恩第一医院长春130021 湖南省肿瘤医院长沙410013 浙江大学医学院附属第一医院杭州310031 南京世和基因生物技术股份有限公司南京210032 佛山市第一人民医院广东佛山528000 四川省肿瘤医院成都610042 陆军军医大学大坪医院重庆400042 不详

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第21届中国肺癌高峰论坛”于2024年3月2日在广州顺利召开。此次论坛以肺癌适应性治疗为主题,从肺癌适应性治疗定义、早中晚期临床应用以及生物标志物... 详细信息

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第21届中国肺癌高峰论坛”于2024年3月2日在广州顺利召开。此次论坛以肺癌适应性治疗为主题,从肺癌适应性治疗定义、早中晚期临床应用以及生物标志物对适应性治疗的指导价值等角度展开探讨并达成了专家共识。

关键词：肺癌适应性治疗共识

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Consensus statement on layout and delivery of automatic external defibrillator in China

引用

Journal of Hainan Medical University 2020年第15期26卷 18-23页

作者： Yu Cao Song chen Yan-Fen Chai Xiao-Hui chen Yu-Guo chen Shao-wen cheng wen-Wei cheng Bang-Han Ding Yang deng Jie Fu Bang-Jiang Fang Mai-Ying Fan Li Gui Ping Gong Wei Guo shu-Bin Guo Liang huang Ji-yuan Han Zhong Ji Xian-Fei Ji Xin-Cai Ji Hong-xu Jin Xin-jun Jiang Wang-Xiang Jiang Jia-Liang Liu Xiao-Ran Liu Zhi Liu Chuan-Zhu Lv Feng Lu Tan-Shi Li Xin Li Yong Li Shang-Lun Li shuang-Ming Li Xiao-Gang Li Bao-jun Li Pei-wu Li Chun-Sheng Li Zhi-jun Li Chang-Luo Li Xiang-Min Li Yin-Ping Li Zong-jun Lu Zu-xun Lu Zhong-Qiu Lu Zhi-Qian Luo Xiao-Xing Liao Jian-Bo Lei Tao Ma Yu Ma Yue-Feng Ma Qing-Bian Ma Lin-Hao Ma jun-Qi Ma Shi-Nan Nie Jie-Miao Ou-Yang Peng Peng Qiao Pei shu-Ming Pan Guo-Zhong Qing Li-Jie Qin wu-Ying Qiao Fei Shao Wei Song Xing-Yue Song Zhen-Ju Song Rong-Ju Sun de-Ya Shang Du-Juan Sha Gui-Lan Tao Guo-Gang Tian Ying-Ping Tian Jian-Guang Tian Chao-Yang Tong Zi-Ren Tang Meng-Xiong Tang Guo-Ping wu Zhi Wan Tao Wang Xin Wang Peng Wang Zhong Wang Tong Wang Ri-Xing Wang Yi-Xin Wang Xiao-Dan Wang Ling wu Wei Wei hua Xiang Feng xu jun xu Jie xu Miao-Rong Xie shuo-Gui xu Tie xu Feng Yu wen Yi Li-Shan Yang Shi-Jiao Yan Jin-Jian Yao Shou-Chun Yan xue-Zhong Yu Xian-Zhi Ye Xian-Liang Yan Fu-Bing zhou Rong-Bin zhou Ming zhou Qiang zhou Jin zhou Ping zhou Chang-Ju Zhu hua-Dong Zhu Ji-Hong Zhu Hong zhang mao zhang hua zhang Na zhang Guo-Qiang zhang Guo-Xiu zhang Jin-Song zhang wen-wu zhang wen-Zhong zhang Jian-Feng zhang Yi-Min Zhu jun Zeng yuan Zheng Zhi-Jie Zheng Shen Zhao Yan Zhao Min Zhao Bin Zhao Xiao-Dong Zhao Xiao-Jing Zhao Hong-Ke Zeng Sheng-Qiang Zou The Chinese Society of Emergency Medicine Research Unit of Island Emergency Medicine Chinese Academy of Medical SciencesHainan Medical University Key Laboratory of Emergency and Trauma of Ministry of Education Hainan Medical UniversityHaikouHainanChina Emergency and Trauma College Hainan Medical UniversityHaikouHainanChina department of Emergency Hainan Clinical Research Center for Acute and Critical DiseasesThe Second Affiliated Hospital of Hainan Medical UniversityHaikouHainanChina Key Laboratory of Hainan Trauma and Disaster Rescue Key Laboratory of Trauma of Hainan Medical University

*** Sudden cardiac death(SCD)refers to sudden death due to a variety of cardiac *** is manifested as a sudden loss of consciousness,cardiac arrest,and respiratory arrest and generally shows early symptoms that are atypical and not easily detected[1].According to a recent study,nearly 544000 patients suffer from SCD every year in China[2].

关键词： cardiac death respiratory

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The DIRECT consortium and the REST-meta-MDD project:towards neuroimaging biomarkers of major depressive disorder

引用

Psychoradiology 2022年第1期2卷 32-42页

作者： Xiao chen Bin Lu Hui-Xian Li xue-Ying Li Yu-Wei Wang Francisco Xavier Castellanos Li-Ping Cao Ning-xuan chen Wei chen Yu-Qi cheng Shi-Xian Cui Zhao-Yu deng Yi-Ru Fang Qi-Yong Gong wen-Bin Guo Zheng-Jia-Yi Hu Li Kuang Bao-Juan Li Le Li Tao Li Tao Lian Yi-Fan Liao Yan-Song Liu Zhe-Ning Liu Jian-Ping Lu Qing-hua Luo hua-Qing Meng Dai-Hui Peng Jiang Qiu Yue-Di Shen Tian-Mei Si Yan-Qing Tang Chuan-Yue Wang Fei Wang hua-Ning Wang Kai Wang Xiang Wang Ying Wang Zi-Han Wang Xiao-Ping wu Chun-Ming Xie Guang-Rong Xie Peng Xie Xiu-Feng xu Hong Yang Jian Yang shu-Qiao Yao Yong-Qiang Yu Yong-Gui yuan Ke-Rang zhang Wei zhang Zhi-jun zhang jun-Juan Zhu Xi-Nian Zuo Jing-Ping Zhao Yu-Feng Zang the DIRECT consortium Chao-Gan Yan CAS Key Laboratory of Behavioral Science Institute of PsychologyChinese Academy of SciencesBeijing 100101China International Big-Data Center for depression Research Chinese Academy of SciencesBeijing 100101China Magnetic Resonance Imaging Research Center Institute of PsychologyChinese Academy of SciencesBeijing 100101China department of Psychology University of Chinese Academy of SciencesBeijing 100049China Sino-Danish College University of Chinese Academy of SciencesBeijing 101408China Sino-Danish Center for Education and Research Graduate University of Chinese Academy of SciencesBeijing 101408China department of Child and Adolescent Psychiatry NYU Grossman School of MedicineNew YorkNY 10016USA Nathan Kline Institute for Psychiatric Research OrangeburgNew YorkNY 10962USA 9Affiliated Brain Hospital of Guangzhou Medical UniversityGuangzhou 510370China Capital Normal University Beijing 100089China department of Psychiatry Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou 310020ZhejiangChina department of Psychiatry First Affiliated Hospital of Kunming Medical UniversityKunmingYunnan 650032China Shanghai Mental Health Center Shanghai Jiao Tong University School of MedicineShanghai 200030China huaxi MR Research Center(HMRRC) Department of RadiologyWest China Hospital of Sichuan UniversityChengduSichuan 610044China Research Unit of Psychoradiology Chinese Academy of Medical SciencesChengduSichuan 610052China department of Psychiatry and National Clinical Research Center for Mental DisordersThe Second Xiangya Hospital of Central South UniversityChangsha 410011HunanChina department of Psychiatry The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400042China Xijing Hospital of Air Force Military Medical University Xi’anShaanxi 710032China Center for Cognitive Science of Language Beijing Language and Culture UniversityBeijing 100083China Affiliated Mental Health Center&Hangzhou Seventh People’s Hospital Zhejiang University School of

despite a growing neuroimaging literature on the pathophysiology of major depressive disorder(MDD),repro-ducible findings are lacking,probably reflecting mostly small sample sizes and heterogeneity in analytic *** address these issues,the depression Imaging REsearch ConsorTium(DIRECT)was *** REST-meta-MDD project,pooling 2428 functional brain images processed with a standardized pipeline across all participating sites,has been the first effort from *** this review,we present an overview of the moti-vations,rationale,and principal findings of the studies so far from the REST-meta-MDD *** from the first round of analyses of the pooled repository have included alterations in functional connectivity within the default mode network,in whole-brain topological properties,in dynamic features,and in functional *** well-powered exploratory observations have also provided the basis for future longitudinal hypothesis-driven *** these fruitful explorations,DIRECT has proceeded to its second stage of data sharing that seeks to examine ethnicity in brain alterations in MDD by extending the exclusive Chinese original sample to other ethnic groups through international collaborations.A state-of-the-art,surface-based preprocessing pipeline has also been introduced to improve *** images from patients with bipolar disorder and schizophrenia will be included to identify shared and unique abnormalities across diag-nosis *** addition,large-scale longitudinal studies targeting brain network alterations following antidepressant treatment,aggregation of diffusion tensor images,and the development of functional magnetic resonance imaging-guided neuromodulation approaches are *** these endeavours,we hope to accelerate the translation of functional neuroimaging findings to clinical use,such as evaluating longitudinal effects of antidepressant medications and developing individualized

关键词： major depressive disorder DIRECT R-fMRI database neuroimaging

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Feasibility and physics potential of detecting ^(8)B solar neutrinos at junO

引用

Chinese Physics C 2021年第2期45卷 93-110页

作者： Angel Abusleme Thomas Adam Shakeel Ahmad Sebastiano Aiello Muhammad Akram Nawab Ali Fengpeng An Guangpeng An Qi An Giuseppe Andronico Nikolay Anfimov Vito Antonelli Tatiana Antoshkina Burin Asavapibhop João Pedro Athayde Marcondes de André Didier Auguste Andrej Babic Wander Baldini Andrea Barresi Eric Baussan Marco Bellato Antonio Bergnoli Enrico Bernieri David Biare Thilo Birkenfeld Sylvie Blin David Blum Simon Blyth Anastasia Bolshakova Mathieu Bongrand Clément Bordereau Dominique Breton Augusto Brigatti Riccardo Brugnera Riccardo Bruno Antonio Budano Max Buesken Mario Buscemi Jose Busto Ilya Butorov Anatael Cabrera Hao Cai Xiao Cai Yanke Cai Zhiyan Cai Antonio Cammi Agustin Campeny Chuanya Cao Guofu Cao jun Cao Rossella Caruso Cédric Cerna Jinfan Chang Yun Chang Pingping chen Po-An chen Shaomin chen Shenjian chen xurong chen Yi-wen chen Yixue chen Yu chen zhang chen Jie cheng Yaping cheng Alexander Chepurnov Davide Chiesa Pietro Chimenti Artem Chukanov Anna Chuvashova Gérard Claverie Catia Clementi Barbara Clerbaux Selma Conforti Di Lorenzo Daniele Corti Salvatore Costa Flavio Dal Corso Christophe de La Taille Jiawei deng Zhi deng Ziyan deng Wilfried depnering Marco Diaz xuefeng Ding Yayun Ding Bayu Dirgantara Sergey Dmitrievsky Tadeas Dohnal Georgy Donchenko Jianmeng Dong Damien Dornic Evgeny Doroshkevich Marcos Dracos Frédéric Druillole shuxian Du Stefano Dusini Martin Dvorak Timo Enqvist Heike Enzmann Andrea Fabbri Lukas Fajt Donghua Fan Lei Fan Can Fang Jian Fang Marco Fargetta Anna Fatkina Dmitry Fedoseev Vladko Fekete Li-cheng Feng Qichun Feng Richard Ford Andrey Formozov Amélie Fournier Haonan Gan Feng Gao Alberto Garfagnini Alexandre Göttel Christoph Genster Marco Giammarchi Agnese Giaz Nunzio Giudice Franco Giuliani Maxim Gonchar Guanghua Gong Hui Gong Oleg Gorchakov Yuri Gornushkin Marco Grassi Christian Grewing Maxim Gromov Vasily Gromov Minghao Gu Xiaofei Gu Yu Gu Mengyun Guan Nunzio Guardone Maria Gul Cong Guo Jingyuan Guo Wanlei Guo Xinheng Guo Yuhang Guo Paul Hackspacher Caren Hagner Ran Han Yan Yerevan Physics Institute YerevanArmenia UniversitéLibre de Bruxelles BrusselsBelgium Universidade Estadual de Londrina LondrinaBrazil Pontificia Universidade Catolica do Rio de Janeiro RioBrazil Pontificia Universidad Católica de Chile SantiagoChile Universidad Tecnica Federico Santa Maria ValparaisoChile Beijing Institute of Spacecraft Environment Engineering BeijingChina Beijing Normal University BeijingChina China Institute of Atomic Energy BeijingChina Institute of High Energy Physics BeijingChina North China Electric Power University BeijingChina School of Physics Peking UniversityBeijingChina Tsinghua University BeijingChina University of Chinese Academy of Sciences BeijingChina Jilin University ChangchunChina College of Electronic Science and Engineering National University of Defense TechnologyChangshaChina Chongqing University ChongqingChina Dongguan University of Technology DongguanChina Jinan University GuangzhouChina Sun Yat-Sen University GuangzhouChina Harbin Institute of Technology HarbinChina University of Science and Technology of China HefeiChina The Radiochemistry and Nuclear Chemistry Group in University of South China HengyangChina wuyi University JiangmenChina Shandong University JinanChina Institute of Modern Physics Chinese Academy of SciencesLanzhouChina Nanjing University NanjingChina Guangxi University NanningChina East China University of Science and Technology ShanghaiChina School of Physics and Astronomy Shanghai Jiao Tong UniversityShanghaiChina Tsung-Dao Lee Institute Shanghai Jiao Tong UniversityShanghaiChina Institute of Hydrogeology and Environmental Geology Chinese Academy of Geological SciencesShijiazhuangChina Nankai University TianjinChina wuhan University WuhanChina Xi’an Jiaotong University Xi’anChina Xiamen University XiamenChina School of Physics and Microelectronics Zhengzhou UniversityZhengzhouChina Institute of Physics National Chiao-Tung University Hsinchu National United University Miao-Li department of Physics National T

The Jiangmen Underground Neutrino Observatory(junO)features a 20 kt multi-purpose underground liquid scintillator sphere as its main *** of junO's features make it an excellent location for^8B solar neutrino measurements,such as its low-energy threshold,high energy resolution compared with water Cherenkov detectors,and much larger target mass compared with previous liquid scintillator *** this paper,we present a comprehensive assessment of junO's potential for detecting^8B solar neutrinos via the neutrino-electron elastic scattering process.A reduced 2 MeV threshold for the recoil electron energy is found to be achievable,assuming that the intrinsic radioactive background^(238)U and^(232)Th in the liquid scintillator can be controlled to 10^(-17)g/*** ten years of data acquisition,approximately 60,000 signal and 30,000 background events are *** large sample will enable an examination of the distortion of the recoil electron spectrum that is dominated by the neutrino flavor transformation in the dense solar matter,which will shed new light on the inconsistency between the measured electron spectra and the predictions of the standard three-flavor neutrino oscillation *** m^(2)_(21)=4.8times10^(-5);(7.5times10^(-5))eV^(2),junO can provide evidence of neutrino oscillation in the Earth at approximately the 3sigma(2sigma)level by measuring the non-zero signal rate variation with respect to the solar zenith ***,junO can simultaneously measuredelta m^2_(21)using^8B solar neutrinos to a precision of 20% or better,depending on the central value,and to sub-percent precision using reactor antineutrinos.A comparison of these two measurements from the same detector will help understand the current mild inconsistency between the value of delta m^2_(21)reported by solar neutrino experiments and the KamLAND experiment.

关键词： neutrino oscillation solar neutrino junO

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：